Strategic collaboration for novel anti-CTLA-4
BioNTech announced strategic collaboration with OncoC4 to co-develop anti-CTLA-4 antibody, ONC-392. Compared to currently approved anti-CTLA-4, ONC-392 is expected to have a differentiated safety profile with initial results from the ongoing phase 1/2 PRESERVE-001 study showing favourable therapeut
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.